Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma: a simplified risk scoring system
In brief
Score of 4-6 predicts central node metastasis in 62% of micro-carcinoma patients
A four-factor bedside score (male gender, tumor >5 mm, multifocality, extrathyroidal extension) stratified papillary thyroid microcarcinoma patients, with a high-risk group (score 4-6) showing a 62% chance of central lymph node spread and an overall accuracy (AUC) of about 0.74. Scores up to 1 may allow less extensive surgery, but the model still needs external validation.
- Journal
- Frontiers in endocrinology (Q1)
- Published
- 7 September 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Shuo Liu, Jing Zhang
- PMID
- 42769149
- DOI
- 10.3389/fendo.2026.1833331
Why clinicians should know about it
- Picked for Breast and Endocrine Surgery (paper of the day, 24 September 2026): Risk scoring for CLNM in PTMC
Abstract
BACKGROUND: Central lymph node metastasis (CLNM) occurs in 20-50% of papillary thyroid microcarcinoma (PTMC) patients and influences surgical decision-making. Existing predictive models require complex calculations or specialized tools, limiting clinical utility. This study aimed to develop a simplified risk scoring system for preoperative CLNM prediction using readily available clinical variables. METHODS: This retrospective cohort study included 486 PTMC patients who underwent thyroid surgery with prophylactic central neck dissection between January 2022 and January 2026. Multivariate logistic regression identified independent predictors of CLNM. A simplified risk scoring system was developed by multiplying regression coefficients (β) by 2 and rounding to integers. Internal validation was performed using bootstrap resampling (1000 iterations). RESULTS: Four independent predictors were identified: male gender (β=0.52, adjusted OR 1.68, 95% CI 1.12-2.53), tumor size >5 mm (β=0.76, adjusted OR 2.14, 95% CI 1.45-3.16), multifocality (β=0.64, adjusted OR 1.89, 95% CI 1.23-2.91), and extrathyroidal extension (β=1.02, adjusted OR 2.76, 95% CI 1.68-4.53). The scoring system assigned 1 point each for male gender and multifocality, and 2 points each for tumor size >5 mm and extrathyroidal extension (total score 0-6). The apparent AUC was 0.742 (95% CI 0.698-0.786), with optimism-corrected AUC of 0.738. Risk stratification demonstrated progressive CLNM rates: very low-risk (score 0, 0%), low-risk (score 1, 22.3%), intermediate-risk (scores 2-3, 34.6%), and high-risk (scores 4-6, 62.2%) (p for trend <0.001). CONCLUSIONS: This simplified four-variable scoring system effectively stratifies CLNM risk in PTMC using preoperatively available data. Patients with score ≤1 may be considered for less extensive surgery or active surveillance, while those with score ≥4 should be considered for prophylactic central neck dissection. This practical tool enables immediate bedside risk assessment without specialized software, though external validation is warranted.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.